ARN-509

enzalutamide · Aragon Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ARN-509, covering 2013-09-13 to 2020-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer [Phase 2]